Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME -- Ignore unavailable to you. Want to Upgrade?

To: LJM who wrote (186)	8/2/2007 12:35:12 PM
From: keokalani'nui	Respond to of 285

Thank you LJM. Appreciate it plenty.

To: LJM who wrote (186)	8/30/2007 9:28:15 AM
From: tuck	Read Replies (1) \| Respond to of 285

>>8:33AM Cardiome Pharma And Astellas announce regulatory extension (CRME) 9.32 : Co and its co-development partner Astellas Pharma announce that the FDA has requested that Astellas and CRME participate in a panel review to be conducted by the Cardiovascular and Renal Drugs Advisory Committee on Dec 11-12, 2007. The New Drug Application for the intravenous formulation of vernakalant hydrochloride, an investigational new drug for the acute conversion of atrial fibrillation, will be reviewed as part of a two-day meeting regarding therapies for acute conversion of heart arrhythmias.<< Courtesy of Briefing.com. Sigh. Glad I sold those calls. Cheers, Tuck